BTAI BioXcel Therapeutics Inc.

11
0  0%
Previous Close 11
Open 11.19
Price To Book 5.31
Market Cap 172323822
Shares 15,665,802
Volume 21,620
Short Ratio
Av. Daily Volume 38,199

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated soon with Phase 3 pivotal trial to commence 2H 2019
BXCL501
Schizophrenia - Agitation
Phase 1/2 initial data due 2H 2019.
BXCL701 and Keytruda
Neuroendocrine Prostate Cancer (tNEPC)
Phase 1/2 initial data due 2H 2019.
BXCL701
Pancreatic cancer

Latest News

  1. BioXcel Therapeutics Achieved Targeted Exposures of BXCL501 Designed For Non-Invasive Acute Treatment of Agitation in Neuropsychiatric Diseases
  2. BioXcel Therapeutics to Highlight Advances in the BXCL501 Program at 2019 Investor Event in New York City
  3. BioXcel Therapeutics to Present at the 2019 UBS Global Healthcare Conference
  4. BioXcel Therapeutics Reports First Quarter 2019 Results and Provides Business Update
  5. BioXcel Therapeutics Advances Process Development for BXCL501 Thin Film Formulation
  6. BioXcel Therapeutics to Host First Quarter 2019 Financial Results and Business Update
  7. Does BioXcel Therapeutics's (NASDAQ:BTAI) Share Price Gain of 46% Match Its Business Performance?
  8. BioXcel Therapeutics to Present at Upcoming Investor Conferences in April
  9. BioXcel Therapeutics Showcases Data on BXCL701 in Combination with OX40 Agonist in Late-breaking Poster Presentation at AACR Annual Meeting
  10. BioXcel Therapeutics Files Clinical Trial Application for the Development of BXCL701 and Pembrolizumab in Neuroendocrine Prostate Cancer (tNEPC)
  11. BioXcel Therapeutics to Present at 29th Annual Oppenheimer Healthcare Conference
  12. BioXcel Therapeutics Announces Late Breaking Data Presentation at AACR 2019 Annual Meeting
  13. BioXcel Therapeutics Reports Fourth Quarter and Full Year 2018 Quarterly Results and Provides Business Update
  14. BioXcel Therapeutics to Participate in Upcoming Investor Conferences in March
  15. BioXcel Therapeutics Announces Addition of Merck KGaA, Darmstadt, Germany, and Pfizer to Clinical Collaboration with Nektar for Development of Triple-combination Therapy in Pancreatic Cancer
  16. BioXcel Therapeutics to Host Fourth Quarter & Full Year 2018 Financial Results and Business Update Conference Call
  17. BioXcel Therapeutics to Present at 2019 BIO CEO & Investor Conference
  18. BioXcel Therapeutics Expands Indication for Lead Neuroscience Asset, BXCL501, to Treat Symptoms Associated with Opioid Drug Withdrawal
  19. The Most Innovative Healthcare AI Developments of 2019
  20. BioXcel Therapeutics Reports Positive Human Proof-of-Concept Data for Acute Treatment of Agitation in Patients with Alzheimer’s Disease